AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05735860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
Study NCT05735860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Description: Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
Study NCT06541509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed.
Study NCT05003752 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External beam radiation therapy, High-dose-rate brachytherapy
Description: Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
Study NCT05003752 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Goserelin 10.8 mg
Description: Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
Study NCT06124716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced COACH CDS Tool
Description: CDS tool with features to promote high blood pressure management
Study NCT06124716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care COACH CDS Tool
Description: CDS tool with limited features to promote high blood pressure management
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously (IV).
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles.
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
Study NCT04778397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroidal Eye Drops
Description: Administered per institutional standard during consolidation.
Study NCT05419960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vestibular Assessment
Description: During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)
Study NCT05419960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Petrous bone Computed Tomography (CT)
Description: For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear.
Study NCT05419960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings.
Study NCT06514001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX-2011P
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Study NCT05659927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-ZG122 Humanized Monoclonal Antibody Injection
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
Study NCT05659927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
Study NCT04767009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)
Description: Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
Study NCT04767009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
Study NCT05705622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral mukositis nurse's education for patients
Description: Education given to patients by nurses on the prevention, treatment and care of oral mucositis
Study NCT05395962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: treatment with bleomycin and carboplatin in association with electroporation
Study NCT05395962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: treatment with bleomycin in association with electroporation
Study NCT05395962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: treatment with bleomycin in association with electroporation
Study NCT05289921 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HU-014 Inj
Description: HU-014 Inj was given an injection to 5 Upper limb muscle
Study NCT05289921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HU-014 Inj
Description: HU-014 Inj was given an injection to 5 Upper limb muscle
Study NCT05214976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)
Description: Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
Study NCT06382324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness practice of body scan
Description: Mindfulness intervention is one kind of psychological intervention. The founder of Mindfulness-Based Stress Reduction (MBSR), Jon Kabat-Zinn, described mindfulness as \&#34;awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally\&#34; (Kabat-Zinn, 2003). Moreover, these attitudes can be nurtured through various practices such as body scan, meditation, yoga, mindful eating, and mindful walking. Mindfulness practices are recognized for their ability to alleviate stress among athletes and enhance their recovery capabilities (Li et al., 2019). Mindfulness practice has been shown to enhance athletes\&#39; performance (Chen et al., 2018)、 improve sleep quality (Rusch et al., 2019)，which in turn promotes emotional stability and physical recovery.
Study NCT06382324 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: listening to light music
Description: listening to light music asa control
Study NCT05463978 — intervention group
Intervention type: DEVICE
Intervention: Sculptra Aesthetic
Description: Sculptra Aesthetic in non-facial areas
Study NCT06539793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.
Study NCT06539793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as strong but comfortable (SC1). The duration will be for 30 minutes, 3times/ week for 4 weeks
Study NCT05809999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard colonoscopy with targeted biopsies
Description: Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
Study NCT06542679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: A mobile health application based on Social Cognitive Theory (SCT) and the Information-Motivation-Behavioral Skills (IMB) model has been developed. The design of the mobile health application is grounded in SCT, the IMB model, and behavioral change interventions and techniques. The content of the mobile application is based on the 'Healthy Weight Gain Guide for Pregnancy.' The application offers a comprehensive program that provides evidence-based recommendations using self-monitoring, feedback, shaping information, goal setting, planning, and reward techniques for healthy nutrition, physical activity, and optimal gestational weight gain for pregnant women.
Study NCT04633382 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after biliary tract surgery
Description: Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
Study NCT04633382 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced recovery after biliary tract surgery
Description: Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
Study NCT06270914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inclusive Positive Behavior Interventions and Supports
Description: The intervention is based on the Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling). The Norwegian model shares its core components with the original SW-PBIS model. The program's core components constitute: (a) positive behavior support strategies, including positive expectations and classroom rules, which are followed up with positive feedback and encouragement; (b) a system for monitoring student behavior, (c) school-wide corrections using consequences, (c) instruction in classroom management skills for teachers, and (e) strategies for collaboration with parents. These components are implemented through activities at school level and at classroom level.
Study NCT06270914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inclusive Positive Behavior Interventions and Supports
Description: The intervention is based on the Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling). The Norwegian model shares its core components with the original SW-PBIS model. The program's core components constitute: (a) positive behavior support strategies, including positive expectations and classroom rules, which are followed up with positive feedback and encouragement; (b) a system for monitoring student behavior, (c) school-wide corrections using consequences, (c) instruction in classroom management skills for teachers, and (e) strategies for collaboration with parents. These components are implemented through activities at school level and at classroom level.
Study NCT04340739 — intervention group
Intervention type: OTHER
Intervention: online patient education teach mindfulness based stress reduction
Description: This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
Study NCT06421038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme honey
Description: Thyme honey is a rich monofloral honey variety formed by bees that collect nectar from thymus vulgaris flowers. thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days
Study NCT06421038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g)
Study NCT05330208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1816
Description: SHR-1816
Study NCT05330208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06462183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-61159
Description: Oral MYB inhibitor
Study NCT05955768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disposable cervical dilator stick combined with lidocaine hydrochloride injection
Description: The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
Study NCT05955768 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Disposable cervical dilator stick combined with normal saline injection
Description: The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
Study NCT05184634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL ACTIVITY LEVELS
Description: Determination of physical activity levels of MetS individuals
Study NCT05184634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DEPRESSION LEVELS
Description: To determine the depression levels of MetS individuals
Study NCT05184634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FATİGUE SEVERİTY
Description: To determine the severity of fatigue of MetS individuals
Study NCT05184634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QUALITY OF LIFE
Description: To determine the quality of life of MetS individuals
Study NCT04765514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)
Description: Temozolomide or Radiotherapy
Study NCT04765514 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.
Description: Temozolomide will be administered at a dose of 75 mg/m2 daily for a total of 21 days. This will be followed by adjuvant temozolomide (150-200 mg/m2 daily for 5 day
Study NCT05206812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: * durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)
Study NCT06162780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic cardiography (UCG)
Description: Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to American Society of Echocardiography (ASE) guideline.
Study NCT06162780 — intervention group
Intervention type: PROCEDURE
Intervention: TEER
Description: Two commercial cliping systems are available for clinical use: the G3 MitraclipTM and the G4 MitraclipTM (Abbott), DragonflyTM (Dejin), which will be introduced to the Chinese market in 2024, with the specific choice determined by the operator. The patient receives general anaesthesia (intravenous and endotracheal). The operator performs the procedure according to the recommended surgical steps in the product manual, guided by X-ray and trans-esophageal echocardiography. Postoperative MR ≤2+ is considered successful, and if the result is unsatisfactory, 1-2 additional clips are given.
Study NCT06450509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Babble Boot Camp
Description: Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
Study NCT06450509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babble Boot Camp
Description: Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
Study NCT06566651 — intervention group
Intervention type: OTHER
Intervention: Emotion Discrimination Task (EDT)
Description: It estimates the subjective bias and sensitivity in discriminating between happy and angry facial expressions of different intensities of emotional expression
Study NCT05878535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.